Switching Anti-TNF-Alpha Agents in Rheumatoid Arthritis (RA)

Inclusion Criteria: * Diagnosis of Rheumatoid Arthritis * Current treatment with either etanercept or adalimumab for at least 12 weeks prior to randomization * Disease Activity Score (DAS) C-reactive Protein (CRP) 28 ≥ 4.4 * Treatment with concomitant Disease-Modifying Anti-Rheumatic Drugs (DMARDs) is permitted but not required as described below: 1. Methotrexate - maximum dose of 25 mg per os (PO), intra-muscular (IM), or SQ weekly. 2. Leflunomide - maximum dose of 20 mg PO daily. 3. Sulfasalazine - maximum dose of 1,500 mg PO twice daily. 4. Hydroxychloroquine - maximum dose of 400 mg PO daily. * If taking DMARD(s), subjects must be on stable doses for at least 12 weeks prior to randomization. * If treated with prednisone (or equivalent corticosteroid), on a stable dose of \<= 10 mg/day for 28 days prior to randomization. * Agree to use appropriate form of contraception. More information on this criterion can be found in the protocol. Exclusion Criteria: * Diagnosis of another autoimmune disease likely to require immunosuppression. More information on this criterion can be found in the protocol. * Failing treatment with etanercept if previously treated with adalimumab * Failing treatment with adalimumab if previously treated with etanercept * Intraarticular injection within 4 weeks prior to randomization * Concomitant use of DMARDs other than those described in Inclusion Criteria within 12 weeks of randomization. * Concurrent use of any biologic agent other than etanercept or adalimumab * Concomitant immunosuppressive therapy other than the Disease-Modifying Anti-Rheumatic Drugs (DMARDs), non-steroidal anti-inflammatory drugs (NSAIDs), or corticosteroids specified in the protocol * Presence of open leg ulcers * Chronic or persistent infection that may be worsened by immunosuppressive treatment. More information on this criterion can be found in the protocol. * Active infection or severe infections requiring hospitalization or treatment with intravenous antibiotics, antivirals, or antifungals within 30 days prior to randomization * History of positive Purified Protein Derivative (PPD) or chest x-ray findings indicative of prior tuberculosis infection * Any medical condition or treatment that, in the opinion of the investigator, would put the subject at risk by participation in the study * History of malignancy. More information on this criterion can be found in the protocol. * Certain abnormal laboratory values. More information on this criterion can be found in the protocol. * Investigational biological or chemical agents within 4 weeks prior to randomization. * History of drug or alcohol abuse within a year prior to randomization * Treatment with natalizumab, rituximab, or another B-cell depleting therapy within a year prior to randomization * Treatment with infliximab, abatacept, tocilizumab, golimumab, or certolizumab pegol within 12 weeks prior to randomization. * Known allergy or hypersensitivity to study products * Any psychiatric disorder that prevents the participant from providing informed consent * Inability to follow protocol instructions * Pregnant or breastfeeding